Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04092764 · ClinicalTrials.gov registry record · NA
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN)
A NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT04092764: Completed NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04092764 is a NA study of Chemotherapy-induced Peripheral Neuropathy that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 23 participants, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04092764, a NA study of Chemotherapy-induced Peripheral Neuropathy, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the validity of a point-of-care nerve conduction device (NeuroMetrix) and Rydel-Seiffer tuning fork in assessing the level of peripheral neuropathy in patients with chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy-induced peripheral neuropathy (CIPN) is a common, persistent toxicity among patients who receive chemotherapy. It is characterized by a variety of sensory and motor symptoms such as numbness, tingling, reduced sense of touch, reduced proprioception (awareness of your limb and body position in space), pain, weakness, balance disturbances, and deficits in motor skills.
Primary Outcome
Participants with chemotherapy-induced peripheral neuropathy (CIPN) will have their level of periphal neuropathy assessed with the Rydel-Seiffer Tuning Fork while using a point-of-care conduction device (NeuroMetrix). The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated
Conditions Studied
Interventions
- DEVICE Electroacupuncture
- DEVICE NeuroMetrix
- DEVICE Rydel-Seiffer tuning fork
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2021-11-11 |
| Phase | NA |
What the finished NCT04092764 record still lists
NCT04092764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 3 interventions - of which Electroacupuncture is the first listed.
NCT04092764 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04092764 about?
NCT04092764 is a clinical study titled "Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN)". The purpose of the study is to determine the validity of a point-of-care nerve conduction device (NeuroMetrix) and Rydel-Seiffer tuning fork in assessing the level of peripheral neuropathy in patients with chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy-induced peripheral neuropathy ...
What is the current status of trial NCT04092764?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2020-01-23. Estimated completion is 2021-11-11.
What conditions does trial NCT04092764 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT04092764?
The interventions under investigation include: Electroacupuncture (DEVICE), NeuroMetrix (DEVICE), Rydel-Seiffer tuning fork (DEVICE).
Who is sponsoring clinical trial NCT04092764?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04092764 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04092764's enrollment target sits among peer trials
23 21st of 29 higher than 9 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression for CIPN
RECRUITING · NA
-
VGAIT for Chemotherapy-induced Peripheral Neuropathy
RECRUITING · NA
-
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
RECRUITING · NA
-
Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · NA
-
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · NA
-
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI